Fig. 2. Evaluation of constipation-type irritable bowel syndrome (IBS-C) symptoms. The proportion of responders with improvement in overall symptoms of IBS-C was 53.33% in the DA-9701 group and 40.00% in the placebo group (P = 0.301). Responder, the patients whose number of weeks in which symptoms were adequately improved in 75% of the total treatment period.
© J Neurogastroenterol Motil
